901 related articles for article (PubMed ID: 8674005)
1. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
3. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
4. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
6. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.
Yaginuma Y; Hayashi H; Kawai K; Kurakane T; Saitoh Y; Kitamura S; Sengoku K; Ishikawa M
Exp Cell Res; 1997 Jun; 233(2):233-9. PubMed ID: 9194486
[TBL] [Abstract][Full Text] [Related]
8. [Mutations of several tumor suppressor genes in primary retinoblastoma].
Huang Q; Tao Y; Yandell DW
Zhonghua Zhong Liu Za Zhi; 1999 Jan; 21(1):10-2. PubMed ID: 11776785
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
10. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the INK4 family of genes in prostate carcinomas.
Park DJ; Wilczynski SP; Pham EY; Miller CW; Koeffler HP
J Urol; 1997 May; 157(5):1995-9. PubMed ID: 9112579
[TBL] [Abstract][Full Text] [Related]
12. [Mutations of p53 gene in 41 cases of human brain gliomas].
Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
[TBL] [Abstract][Full Text] [Related]
13. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers.
Yoshida S; Todoroki T; Ichikawa Y; Hanai S; Suzuki H; Hori M; Fukao K; Miwa M; Uchida K
Cancer Res; 1995 Jul; 55(13):2756-60. PubMed ID: 7796400
[TBL] [Abstract][Full Text] [Related]
14. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
15. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
Sonoda Y; Yoshimoto T; Sekiya T
Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
[TBL] [Abstract][Full Text] [Related]
16. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
[TBL] [Abstract][Full Text] [Related]
17. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
[TBL] [Abstract][Full Text] [Related]
19. Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.
Miyamoto H; Kubota Y; Fujinami K; Dobashi Y; Kondo K; Yao M; Shuin T; Hosaka M
Oncol Res; 1995; 7(7-8):327-30. PubMed ID: 8747595
[TBL] [Abstract][Full Text] [Related]
20. [Analysis on point mutation of the CDKN2/p16 gene in lung cancer].
Su C; Ye Y; Wang D; Cao X; Li S; Shan X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):37-40. PubMed ID: 11836684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
